Avenda Health, an AI healthcare company creating the future of prostate cancer care, has received FDA Investigational Device Exemption (IDE) for its FocalPoint ablation system. The IDE will allow the technology, powered by iQuest, to be used in a randomized control trial to show superiority over the standard of care for the treatment of prostate cancer.
